Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Frontiers in Immunology, 11, Frontiers Media S.A.
- Ereignis
-
Veröffentlichung
- (wo)
-
Darmstadt
- (wer)
-
Universitäts- und Landesbibliothek
- (wann)
-
2024
- DOI
-
10.26083/tuprints-00017467
- URN
-
urn:nbn:de:tuda-tuprints-174678
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:43 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Macarrón Palacios, Arturo
- Grzeschik, Julius
- Deweid, Ludwig Lukas
- Krah, Simon
- Zielonka, Stefan
- Rösner, Thies
- Peipp, Matthias
- Valerius, Thomas
- Kolmar, Harald
- Universitäts- und Landesbibliothek
Entstanden
- 2024
Ähnliche Objekte (12)
Specific targeting of lymphoma cells using semisynthetic anti-idiotype shark antibodies
Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies
Anti-idiotype antibodies for biomedical applications
Intein mediated high throughput screening for bispecific antibodies
Arming Antibodies for Cancer Therapy: Transglutaminase-Mediated Toxin Conjugation
Merge Two into One: Multispecific Symmetric Antibodies for Cancer Immunotherapy
Development of Innovative Bioconjugation Strategies for the Generation of Bi-Specific Antibodies Enabling Targeted Protein Degradation
Modulation of the FKBP51 structure by protein engineering and isolation of conformation-locking antibodies and affibodies
Hybrid Multimeric Architectures for Enhanced Receptor Targeting and Intracellular Delivery of Bioactive Cargoes
Validation and characterization of monoclonal antibodies to target cancer stem cells and to develop new anti-cancer therapies
Engineering IgG-Like Bispecific Antibodies — An Overview
Chicken-derived antibodies for therapeutic, diagnostic and bioprocessing applications
Specific targeting of lymphoma cells using semisynthetic anti-idiotype shark antibodies
Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies
Anti-idiotype antibodies for biomedical applications
Intein mediated high throughput screening for bispecific antibodies
Arming Antibodies for Cancer Therapy: Transglutaminase-Mediated Toxin Conjugation
Merge Two into One: Multispecific Symmetric Antibodies for Cancer Immunotherapy
Development of Innovative Bioconjugation Strategies for the Generation of Bi-Specific Antibodies Enabling Targeted Protein Degradation
Modulation of the FKBP51 structure by protein engineering and isolation of conformation-locking antibodies and affibodies
Hybrid Multimeric Architectures for Enhanced Receptor Targeting and Intracellular Delivery of Bioactive Cargoes
Validation and characterization of monoclonal antibodies to target cancer stem cells and to develop new anti-cancer therapies
Engineering IgG-Like Bispecific Antibodies — An Overview
Chicken-derived antibodies for therapeutic, diagnostic and bioprocessing applications
Specific targeting of lymphoma cells using semisynthetic anti-idiotype shark antibodies
Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies
Anti-idiotype antibodies for biomedical applications
Intein mediated high throughput screening for bispecific antibodies
Arming Antibodies for Cancer Therapy: Transglutaminase-Mediated Toxin Conjugation
Merge Two into One: Multispecific Symmetric Antibodies for Cancer Immunotherapy
Development of Innovative Bioconjugation Strategies for the Generation of Bi-Specific Antibodies Enabling Targeted Protein Degradation
Modulation of the FKBP51 structure by protein engineering and isolation of conformation-locking antibodies and affibodies
Hybrid Multimeric Architectures for Enhanced Receptor Targeting and Intracellular Delivery of Bioactive Cargoes
Validation and characterization of monoclonal antibodies to target cancer stem cells and to develop new anti-cancer therapies
Engineering IgG-Like Bispecific Antibodies — An Overview